Pfizer Inc. and Geron Corporation: Monday's Biggest Losers

While several biotech stocks sold off today in a broader industry sell-off, two stocks in this sector fell today because of their own bad news. Geron (NASDAQ: GERN  ) tumbled by about 15% today, after The Mayo Clinic announced that the trial for Geron's cancer drug Imetelstat for the myelofibrosis indication is closed, though no efficacy data was released. More than 25% of the patients in the trial have now dropped out, which has investors in Geron spooked.

Pfizer (NYSE: PFE  ) also lost today, as the company's lung cancer drug Dacomitinib failed two phase 3 trials. The drug was unable to prolong overall survival rate over the placebo or progression-free survival against Tarceva.

In this video, Motley Fool health-care analyst David Williamson gives investors his thoughts on Geron and Pfizer today.

Biotechs can win big, and lose big. What's the best way to play?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (3) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 28, 2014, at 11:56 PM, johnson12345 wrote:

    Love the Fool, but this article on GERN has it wrong. Enrollment in the Mayo clinic was closed only to NEW enrollment. It was closed because the Clinic was inundated with requests to join the program after it was announced that theirs was the first drug to ever create a remission, partial and complete- in 5 of 22 patients in MF- a remarkable success. The % of patients who have discontinued the IST has DROPPED from the original %. In the first 33 patients, only 9 discontinued- 27%, where in the next 46 patients just 11 stopped- LESS than 25%. The results have improved.

    The stock was most likely down because investors had hoped for an update but were told it will be at the next Cancer Conference. There was no negative news.

  • Report this Comment On January 29, 2014, at 8:25 AM, DrSoul wrote:

    This is a terrible re-cap of Monday's news for Geron by Mr. Williamson. The company did not announce "bad news". It merely announced that it was closed to new patients. The vast majority of patients (75%) are still in the study, and are most likely achieving benefits from Imetelstat which is why they continue to receive the medication.

  • Report this Comment On January 29, 2014, at 10:28 AM, mruyog wrote:

    Mr. Willamson, do your study well before blurting out half truths!! You seem to be an amateur or a paid basher, either of the two. But, please do not think others are fool!!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2811903, ~/Articles/ArticleHandler.aspx, 12/17/2014 6:10:19 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement